View 
FILTERS (0)
* Not connected to ResearchPool

MORE FILTERS

  
reports

Esco Technologies Inc: 1 director

A director at Esco Technologies Inc sold/sold after exercising options 2,498 shares at 225.650USD and the significance rating of the trade was 62/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's direc...

Julius Baer Group Ltd: 1 director

A director at Julius Baer Group Ltd bought 500 shares at 55.273CHF and the significance rating of the trade was 53/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years cl...

Moody's Ratings affirms Cogeco's B1 CFR; outlook changed to stable

Moody's Ratings (Moody's) affirmed Cogeco Communications (USA) Inc.'s (Cogeco or the Company) B1 Corporate Family Rating (CFR) and B1-PD Probability of Default Rating (PDR). We also affirmed the B1 senior secured bank credit facilities ratings at Cogeco Communications Finance (USA), LP, Cogeco US Fi...

Martijn Den Drijver
  • Martijn Den Drijver

Chin Hin Group Berhad: 1 director

A director at Chin Hin Group Berhad bought 6,402,900 shares at 2.000MYR and the significance rating of the trade was 67/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two yea...

 PRESS RELEASE

CMB.TECH announces Q3 2025 results

CMB.TECH announces Q3 2025 results CMB.TECH ANNOUNCES Q3 2025 RESULTSSOFT SUMMER, FOLLOWED BY ROARING TANKER AND DRY BULK MARKETS ANTWERP, Belgium, 26 November 2025 – CMB.TECH NV (“CMBT”, “CMB.TECH” or “the Company”) (NYSE: CMBT, Euronext Brussels: CMBT and Euronext Oslo Børs: CMBTO) reported its unaudited financial results today for the third quarter ended 30 September 2025. HIGHLIGHTSFinancial highlights: Profit for the period of 17.3 million USD in Q3 2025. EBITDA for the same period was USD 238.4 million.CMB.TECH’s contract backlog stands at 2.95 billion USD.Proposal to declare an in...

 PRESS RELEASE

Valneva Announces Positive Final Phase 2 Results for Lyme Disease Vacc...

Valneva Announces Positive Final Phase 2 Results for Lyme Disease Vaccine Candidate Antibody levels remained well above baseline across all six serotypes and age groups sixth month after third yearly booster doseNo safety concerns observed in any age group by an independent Data Monitoring Committee (DMC)Results confirm benefits of a yearly vaccination prior to each Lyme season Saint-Herblain (France), November 26, 2025 –  (Nasdaq: VALN; Euronext Paris: VLA) today announced positive final immunogenicity and safety data from Phase 2 study, VLA15-221, of Lyme disease vaccine candidate, VLA15...

 PRESS RELEASE

Valneva annonce des résultats finaux positifs de Phase 2 pour son cand...

Valneva annonce des résultats finaux positifs de Phase 2 pour son candidat vaccin contre la maladie de Lyme Les taux d'anticorps sont restés supérieurs à leur niveau initial pour les six sérotypes et dans toutes les tranches d’âge six mois après la dernière injection des trois doses de rappel  Aucun problème de sécurité n’a été observé dans toutes les tranches d’âge par le comité indépendant de surveillance des données (DMC) Ces résultats confirment le bénéfice d’une vaccination annuelle avant chaque saison de Lyme Saint-Herblain (France), le 26 novembre 2025 –  (Nasdaq: VALN; Euronext P...

 PRESS RELEASE

Kuros Biosciences to present at the Piper Sandler 37th Annual Healthca...

Kuros Biosciences to present at the Piper Sandler 37th Annual Healthcare Conference Kuros Biosciences to present at the Piper Sandler 37th Annual Healthcare Conference Schlieren (Zürich), Switzerland, November 26, 2025 – Kuros Biosciences (“Kuros” or the “Company”) a leader in innovative biologic technologies, will present at the Piper Sandler 37th Annual Healthcare Conference, taking place December 2–4, 2025 at The Lotte New York Palace in New York City. The Company’s presentation will highlight continued commercial momentum, clinical advancement across the MagnetOs portfolio, and ong...

 PRESS RELEASE

Capital Markets Day of the future Luotea Plc and Lassila & Tikanoja Pl...

Capital Markets Day of the future Luotea Plc and Lassila & Tikanoja Plc today, 26 November LASSILA & TIKANOJA PLC - STOCK EXCHANGE RELEASE - 26 NOVEMBER 2025 AT 8:00 A.M. Capital Markets Day of the future Luotea Plc and Lassila & Tikanoja Plc today, 26 November Lassila & Tikanoja plc (the “Company”) announced on 7 August 2025 the approval of a demerger plan, according to which, the Company’s circular economy business area will be transferred to a new independent company to be incorporated and named Lassila & Tikanoja Plc (the “New Lassila & Tikanoja”). The Company would retain its facilit...

 PRESS RELEASE

Tulevien Luotea Oyj:n ja Lassila & Tikanoja Oyj:n pääomamarkkinapäivä ...

Tulevien Luotea Oyj:n ja Lassila & Tikanoja Oyj:n pääomamarkkinapäivä tänään 26. marraskuuta LASSILA & TIKANOJA OYJ, PÖRSSITIEDOTE, 26.11.2025 KLO 8.00 Tulevien Luotea Oyj:n ja Lassila & Tikanoja Oyj:n pääomamarkkinapäivä tänään 26. marraskuuta Lassila & Tikanoja Oyj (”Yhtiö”) tiedotti 7.8.2025 osittaisjakautumista koskevan jakautumissuunnitelman hyväksymisestä, jonka mukaan Yhtiön kiertotalousliiketoiminta eriytetään perustettavalle uudelle itsenäiselle yhtiölle, jonka nimeksi tulee Lassila & Tikanoja Oyj (“Uusi Lassila & Tikanoja”). Yhtiön kiinteistöpalveluliiketoiminnot jäisivät Yhtiöö...

Marc Hesselink ... (+3)
  • Marc Hesselink
  • CFA
  • Thymen Rundberg

ASML/Back on its long-term trend/BUY

ASML's 3Q25 update signals a more optimistic outlook for 2026 than previously anticipated. Recent announcements of major AI investments reinforce the robust long-term prospects for semiconductor capital expenditures. We expect ongoing increases in lithography intensity, positioning ASML for growth that outpaces the broader industry. Reflecting these positive trends, we reiterate our BUY rating and raise our target price to €1,050 (up from €800).

Erol Danis ... (+2)
  • Erol Danis
  • Koray Pamir

Model Portfolio Update - Removing Aygaz from our Model Portfolio

Following a very strong run and the partial normalization of the core valuation anomaly that underpinned our initial call, we have downgraded Aygaz to Hold from Buy and simultaneously remove it from our model portfolio, while retaining a constructive fundamental stance. Since the inclusion in our model portfolio, the shares are up 23% in USD, outperforming the BIST-100 by 22%. At the time of our rating upgrade, Aygaz’s participation portfolio (Tupras, Opet Aygaz REIC, United LPG, Sendeo) more t...

Jin Yoon
  • Jin Yoon

TPW AGM Update: Meaningful Deceleration in Rev Growth

What’s new: Temple & Webster held its annual general meeting (AGM) today. The company provided a trading update where rev growth decelerated meaningfully compared to the first few weeks of half as consumers remain cautious about their spending. Margins could remain stable despite incremental investments in New Zealand. We lower our PT from A$32 to A$20 on lowered outlook. Our updated PT of A$20 implies 2.6x FY27E EV/Revs. We maintain our BUY rating. Analysts: Jin Yoon

Koray Pamir
  • Koray Pamir

Aygaz - Relative upside compression following strong run. Downgrade to...

Downgraded to Hold on risk/reward normalization: Since our upgrade to Buy on 30 July 2025, Aygaz has delivered a 31% return in USD, outperforming the BIST-100 by 32% and Tupras by 12%. This has substantially eroded the relative valuation cushion. Our 12M TP of TL272/share is unchanged, but implied upside has compressed to 30%, versus 43% for our coverage universe and 40% for our ex-banks coverage. On a 12M rating basis, this moves Aygaz into Hold territory: we continue to like the name fundament...

ABGSC Renewable Energy Research ... (+2)
  • ABGSC Renewable Energy Research
  • Daniel Vårdal Haugland

Alumis Inc: 1 director

A director at Alumis Inc bought 72,212 shares at 7.380USD and the significance rating of the trade was 65/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years clearly sho...

Upwork Inc: 2 directors

Two Directors at Upwork Inc sold/sold after exercising options 72,500 shares at between 17.508USD and 18.202USD. The significance rating of the trade was 63/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the comp...

Loading...
New interest

Save your current filters as a new Interest

Please enter a name for this interest

Email alerts

Would you like to receive real-time email alerts when a new report is published under this interest?

Save This Search

These search results will show up under 'Saved searches' in the left panel

Please enter a name for this saved search

ResearchPool Subscriptions

Get the most out of your insights

Get in touch